Screening for inherited thrombophilia might be warranted among Eastern Mediterranean sickle-βeta-0 thalassemia patients

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 2, 2006, Pages 121-123

  Isma'eel, Hussain ^a   Arnaout, M S ^a   Shamseddeen, Wael ^a   Mahfouz, R ^a   Zeineh, N ^a   Jradi, Oussama ^b   Taher, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Labib Medical Center   (Lebanon)

Author keywords

Pulmonary hypertension; Sickle thalassemia; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE NUCLEOTIDE; BLOOD CLOTTING FACTOR 5 LEIDEN; GUANINE NUCLEOTIDE; PROTHROMBIN; PYRIMIDINE NUCLEOTIDE;

ANAMNESIS; ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; BLOOD SAMPLING; CLINICAL ARTICLE; CONSANGUINITY; DNA DETERMINATION; DOPPLER ECHOGRAPHY; FEMALE; GENE CLUSTER; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; INCIDENCE; LEBANON; MALE; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; PATIENT SELECTION; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SAMPLE SIZE; SICKLE CELL ANEMIA; SOUTHERN EUROPE; STATISTICAL SIGNIFICANCE; THROMBOPHILIA; THROMBOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; CASE-CONTROL STUDIES; CHILD; CONSANGUINITY; DNA MUTATIONAL ANALYSIS; ECHOCARDIOGRAPHY, DOPPLER; FACTOR V; FEMALE; GENETIC SCREENING; GENETIC TESTING; HUMANS; LEBANON; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; PROTHROMBIN; THROMBOPHILIA;

EID: 33749186021     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-8953-3     Document Type: Article

References (9)

1. Chiang EY, Frenette PS (2005) Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 19(5):771-784
2. Castro O, Gladwin MT (2005) Pulmonary hypertension in sickle cell disease: Mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 19(5):881-896
3. Eldor A, Rachmilewitz EA (2002) The hypercoagulable state in thalassemia. Blood 99:36-43
4. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M (2005) Thalassemia heart disease: A comparative evaluation of thalassemia major and thalassemia intermedia. Chest 127(5):1523-1530
5. Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A (2001) High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: Is the Eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 86(2):723-724
6. Tamim H, Finan RR, Almawi WY (2002) Prevalence of two thrombophilia predisposing mutations: Factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost 88(4):691-692.
7. Isma'eel H, El Accaoui R, Shamseddeen W, Taher A, Alam S, Mahfouz R, Arnaout MS (2005) Genetic thrombophilia in patients with VTE in Eastern Mediterranean located tertiary care center; Is it time to change the algorithm for thrombophilia work up decision making? J Thromb Thrombolysis (In press)
8. Otrock ZK, Mahfouz RA, Taher AT (2005) Should we screen Eastern Mediterranean sickle beta-thalassemia patients for inherited thrombophilia? J Thromb Haemost 3(3):599-600
9. Bauer KA (2001) The thrombophilias: Well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 135:367